Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL
| Autor: | Michael Pfreundschuh, Bernd Metzner, Samira Zeynalova, Marion Hoffmann, Michael R. Clemens, M. Loeffler, Marita Ziepert, Christine Nickenig, N. Schmitz, Viola Poeschel, Hjalmar Steinhauer, Eva Lengfelder, A. D. Ho, R. H. Mertelsmann, Lorenz Truemper, H. Mergenthaler |
|---|---|
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 29:8029-8029 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 8029 Background: Interval reduction from 3 (CHOP-21) to 2 wks (CHOP-14) and the addition of R to CHOP-21 (R-CHOP-21) improved outcome in elderly pts with DLBCL to a similar extent compared to CHOP-21. Methods: In the RICOVER-60 trial, elderly pts.(61-80 yrs) were randomized to receive 6 or 8 cy CHOP-14 with or without 8 cy R. RX was planned to sites of initial bulk and/or extranodal inv. The primary endpoint was EFS, secondary endpoints were PFS and OS. Results:Between 07/2000 and 06/2005, 1,222 pts with CD20+ DLBCL were recruited and are evaluable (med age 68 yrs; IPI=1: 30%, IPI=2: 28%, IPI=3: 26%, IPI=4,5: 16%). There was no difference between the 4 arms with respect to long-term tox and 2nd neoplasms. As by intention to treat, the 7-yr EFS rate was 33% after 6xCHOP-14 (n=307), 40% after 8xCHOP-14 (n=305), 50% after 6xR-CHOP-14 (n=306), and 52% after 8xR-CHOP-14 (n=306). After a median obs time of 82 mo, the estimated 7-yr OS rates were 50% for 6xCHOP-14, 52% for 8xCHOP-14, 62% for 6xR-CHOP-14, and 60%... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|